CAI
Caris Life Sciences, Inc.
Next earnings Aug 10, 2026 · consensus $0.01 EPS, $241M rev
Last earnings +3.7% on 2026-05-07
$18.50
▼ -1.07%$18.50▼ -28.68%
over 1Y
L $14.55EODHDH $39.30
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.1%
1W+6.9%
1M+20.3%
3M+9.1%
YTD-31.4%
1Y-28.7%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 16 analysts
Strong Buy
Precision-oncology diagnostics scaling fast — revenue +97%, now operating-income positive, cash-rich post-IPO — but still GAAP-loss.
Revenue $812M · FY2025
Caris Life Sciences is a precision-oncology / AI-TechBio company that profiles cancer at the molecular level (MI Profile tissue platform, blood-based Caris Assure, and the FDA-approved MI Cancer Seek companion diagnostic). It has built what it believes is one of the largest multi-modal clinico-genomic datasets in oncology, with over 1,000,000 cases profiled, and partners with blue-chip biopharma (Moderna, AbbVie, Merck KGaA, Genentech). The growth is exceptional: FY2025 revenue nearly doubled, up 97.0% to $812M, with clinical case volume rising to 199,300 from 162,850, driven by the 2025 broad launch of MI Cancer Seek and ramping Caris Assure adoption.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $306M | $412M | $812M |
| Gross profit | — | — | — |
| Operating income | -$320M | -$257M | $45.1M |
| Net income | -$341M | -$282M | -$68.1M |
| Diluted EPS | -$13.24 | -$10.66 | -$3.22 |
| Net margin | -111.5% | -68.4% | -8.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.81B
EV / EBITDA71.0
EV / Sales5.9
EV / FCF71.9
P / FCF78.1
PEG (trailing)—
Earnings yield-1.3%
FCF yield1.3%
Quality & risk
ROIC (est.)3.7%
Free cash flow$66.9M
Total debt$379M
Net cash$417M
Altman Z-Score4.33 safe
Piotroski F-Score5/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-04-02). Worth a closer look.
Recent filings
all on EDGAR ↗CERTFiling2026-06-16open ↗8-A12BFiling2026-06-16open ↗8-KPeriod ending 2026-06-042026-06-05open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-152026-05-18open ↗4Period ending 2026-05-152026-05-18open ↗4Period ending 2026-05-152026-05-18open ↗4Period ending 2026-05-152026-05-18open ↗4Period ending 2026-05-152026-05-18open ↗SCHEDULE 13G/AFiling2026-05-12open ↗SCHEDULE 13G/AFiling2026-05-12open ↗
Frequently asked
- Is Caris Life Sciences, Inc. (CAI) a buy?
- CAI currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Precision-oncology diagnostics scaling fast — revenue +97%, now operating-income positive, cash-rich post-IPO — but still GAAP-loss.
- What is Caris Life Sciences, Inc.'s quality score?
- CAI scores 60.09803921568626/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002019410, latest 10-Q filed 2026-05-08) · EODHD · analysis by claude-code · as of 6/21/2026, 8:59:29 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.